Another study found that the antitumoral activity of the BET inhibitor ABBV-075 in SCLC was partially dependent on the inhibition of BCL2, an anti-apoptotic protein (Lam et al., 2017). The gene discussed is BCL2; the disease is small cell lung carcinoma.